Article info
Review
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom
- Correspondence to Professor Sudha Sundar, Pan-Birmingham Gynaecological Cancer Centre, Birmingham B152TT, UK; sudha.sundar{at}nhs.net
Citation
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom
Publication history
- Received October 5, 2020
- Revision received December 6, 2020
- Accepted December 9, 2020
- First published January 19, 2021.
Online issue publication
January 08, 2022
Article Versions
- Previous version (8 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.